Projects per year
Abstract
Tamoxifen binds to estrogen receptor α (ERα) to elicit distinct responses that vary by cell/tissue type and status, but the factors that determine these differential effects are unknown. Here we report that the transcriptional corepressor BASP1 interacts with ERα and in breast cancer cells, this interaction is enhanced by tamoxifen. We find that BASP1 acts as a major selectivity factor in the transcriptional response of breast cancer cells to tamoxifen. 40% of the genes that are regulated by tamoxifen in breast cancer cells are BASP1-dependent, including several genes that are associated with tamoxifen resistance. BASP1 elicits tumour-suppressor activity in breast cancer cells and enhances the anti-tumourigenic effects of tamoxifen treatment. Moreover, BASP1 is expressed in breast cancer tissue and is associated with increased patient survival. Our data has identified BASP1 as an ERα cofactor that plays a central role in the transcriptional and anti-tumourigenic effects of tamoxifen.
Original language | English |
---|---|
Article number | e2771 |
Number of pages | 10 |
Journal | Cell Death and Disease |
Volume | 8 |
Issue number | 5 |
DOIs | |
Publication status | Published - 11 May 2017 |
Keywords
- BASP1
- Estrogen receptor
- ERα
- Tamoxifen
- Breast cancer
- Transcription
Fingerprint
Dive into the research topics of 'BASP1 interacts with estrogen receptor α and modifies the tamoxifen response'. Together they form a unique fingerprint.Projects
- 2 Finished
-
The regulation of Wilms' tumour 1 by phospholipid
Roberts, S. G. E. (Principal Investigator)
1/05/13 → 1/05/16
Project: Research
-
The role of TFIIB phosphorylation in the transcriptional stress response
Roberts, S. G. E. (Principal Investigator)
1/02/13 → 1/02/16
Project: Research